Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Takeda Pharmaceutical
(OTCPK:TKPHF)
Intraday
$26.055
1.015
[4.05%]
Get Report
Watch
Perks
Buy
Compare Brokers
$26.055
1.015
[4.05%]
At close: Apr 26
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Takeda Pharmaceutical Stock (OTC:TKPHF)
Takeda Pharmaceutical Stock (OTC: TKPHF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, May 11, 2023
Takeda Moves Out From Licensing Agreement With Theravance Biopharma
Vandana Singh
-
May 11, 2023, 1:41PM
Takeda's FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues
Vandana Singh
-
May 11, 2023, 8:50AM
Friday, April 21, 2023
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review
Vandana Singh
-
Apr 21, 2023, 12:38PM
Monday, March 20, 2023
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says
Vandana Singh
-
Mar 20, 2023, 10:21AM
Tuesday, February 21, 2023
Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant Patients
Vandana Singh
-
Feb 21, 2023, 9:17AM
Thursday, February 02, 2023
Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged
Vandana Singh
-
Feb 2, 2023, 7:53AM
Monday, January 09, 2023
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
Vandana Singh
-
Jan 9, 2023, 10:12AM
Tuesday, December 13, 2022
Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B
Vandana Singh
-
Dec 13, 2022, 9:55AM
Wednesday, November 23, 2022
Takeda's Dengue Vaccine Candidate Under FDA Priority Review
Vandana Singh
-
Nov 23, 2022, 8:51AM
Thursday, November 17, 2022
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
Vandana Singh
-
Nov 17, 2022, 1:26PM
Thursday, October 27, 2022
Takeda Posts Lower 1H Profit, Lifts FY22 Outlook
Vandana Singh
-
Oct 27, 2022, 8:46AM
Friday, October 14, 2022
European Regulator Backs Approval Of Takeda's Dengue Vaccine
Vandana Singh
-
Oct 14, 2022, 11:33AM
Wednesday, October 05, 2022
Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids
Vandana Singh
-
Oct 5, 2022, 1:31PM
Tuesday, August 30, 2022
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
Vandana Singh
-
Aug 30, 2022, 12:28PM
Friday, August 26, 2022
After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact
Vandana Singh
-
Aug 26, 2022, 7:37AM
Wednesday, July 27, 2022
EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets
Vandana Singh
-
Jul 27, 2022, 6:45AM
Thursday, July 21, 2022
Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder
Vandana Singh
-
Jul 21, 2022, 10:34AM
Friday, July 01, 2022
Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
Vandana Singh
-
Jul 1, 2022, 10:28AM
Wednesday, May 11, 2022
Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22
Vandana Singh
-
May 11, 2022, 6:30AM
Friday, April 22, 2022
Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients
Vandana Singh
-
Apr 22, 2022, 12:10PM
Tuesday, March 08, 2022
Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection
Vandana Singh
-
Mar 8, 2022, 8:53AM
Tuesday, February 22, 2022
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
Vandana Singh
-
Feb 22, 2022, 12:51PM
Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics
Vandana Singh
-
Feb 22, 2022, 12:42PM
Friday, February 18, 2022
Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months
Vandana Singh
-
Feb 18, 2022, 10:46AM
Monday, January 31, 2022
FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder
Vandana Singh
-
Jan 31, 2022, 12:27PM
Wednesday, December 22, 2021
FDA Rejects Takeda's Eosinophilic Esophagitis Candidate, Asks For Additional Study
Vandana Singh
-
Dec 22, 2021, 8:11AM
Thursday, December 16, 2021
Novavax Files For Approval Of Its COVID-19 Vaccine In Japan
Vandana Singh
-
Dec 16, 2021, 5:46AM
Wednesday, November 24, 2021
Takeda's Maribavir Scores FDA Approval For Post-Transplant CMV Infection
Vandana Singh
-
Nov 24, 2021, 6:45AM
Tuesday, November 09, 2021
Takeda, Shattuck Labs Terminate Immuno-Oncology Pact
Vandana Singh
-
Nov 9, 2021, 1:19PM
Thursday, October 28, 2021
Takeda's 1H Sales Increase 13%, Reaffirms FY21 Outlook, Announces Share Buyback
Vandana Singh
-
Oct 28, 2021, 7:26AM
Wednesday, October 27, 2021
Takeda Expands Oncology Pipeline With Cell Therapy Startup Buyout
Vandana Singh
-
Oct 27, 2021, 12:03PM
Tuesday, October 19, 2021
Wave Life Sciences, Takeda Discontinue Research On Preclinical CNS Programs
Vandana Singh
-
Oct 19, 2021, 6:54AM
Calithera Buys Two Oncology Candidates From Takeda For $45M
Vandana Singh
-
Oct 19, 2021, 6:51AM
Wednesday, October 06, 2021
Takeda Discontinues Two Mid-Stage Narcolepsy Trials
Vandana Singh
-
Oct 6, 2021, 5:54AM
Friday, October 01, 2021
Takeda Says 'Human Error' Reason Behind Contaminated Moderna COVID-19 Vaccines
Vandana Singh
-
Oct 1, 2021, 9:09AM
Thursday, September 30, 2021
Takeda In-Licenses Hunter Syndrome Candidate
Vandana Singh
-
Sep 30, 2021, 7:18AM
Friday, September 24, 2021
Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug
Vandana Singh
-
Sep 24, 2021, 1:16PM
Tuesday, September 21, 2021
Mirum, Takeda Ink Maralixibat Licensing Pact In Japan
Vandana Singh
-
Sep 21, 2021, 11:00AM
Thursday, September 02, 2021
Takeda's Breakthrough Blood Cancer Drug Flunks In Phase 3 Study
Vandana Singh
-
Sep 2, 2021, 10:13AM
Monday, August 30, 2021
UK's NICE Rejects Johnson & Johnson's Darzalex Regime For Newly Diagnosed Myeloma
Vandana Singh
-
Aug 30, 2021, 8:27AM
Moderna Withdraws Additional COVID-19 Shots In Japan: What You Need To Know
Vandana Singh
-
Aug 30, 2021, 6:50AM
Thursday, August 26, 2021
Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer
Vandana Singh
-
Aug 26, 2021, 7:51AM
Wednesday, July 28, 2021
Takeda's Narcolepsy Candidate Gets FDA Breakthrough Therapy Tag
Vandana Singh
-
Jul 28, 2021, 11:22AM
Tuesday, July 20, 2021
Japan To Buy Additional 50M Doses Of Moderna COVID-19 Vaccine
Vandana Singh
-
Jul 20, 2021, 7:16AM
Monday, May 24, 2021
Takeda's Dengue Vaccine Effective In Reducing Hospitalization Regardless Of Prior Infection
Vandana Singh
-
May 24, 2021, 8:05AM
Friday, May 21, 2021
Takeda's Maribavir US Application For Post-Transplant CMV Infection Under Review
Vandana Singh
-
May 21, 2021, 8:16AM
Moderna's COVID-19 Vaccine Scores Emergency Use Nod In Japan
Vandana Singh
-
May 21, 2021, 7:49AM
Tuesday, May 11, 2021
Takeda FY20 Profit Surges, Revenue Drops; Guides For Weak FY21 Profit
Vandana Singh
-
May 11, 2021, 6:35AM
Monday, April 05, 2021
Molecular Templates Stock Falls After It Stops MT-3724 Development In Hematological Malignancies
Vandana Singh
-
Apr 5, 2021, 11:48AM
Tuesday, March 30, 2021
Takeda, BridGene To Pursue Undruggable Neurodegenerative Targets
Vandana Singh
-
Mar 30, 2021, 1:56PM
Show more
